# Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

> **NCT04134000** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Fundacion Oncosur** · enrollment: 40 (estimated)

## Conditions studied

- Invasive Bladder Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** BCG

## Key facts

- **NCT ID:** NCT04134000
- **Lead sponsor:** Fundacion Oncosur
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-03
- **Primary completion:** 2024-06
- **Final completion:** 2024-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134000, "Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04134000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*